Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 322.00
Bid: 322.00
Ask: 323.00
Change: 7.00 (2.22%)
Spread: 1.00 (0.311%)
Open: 310.00
High: 322.50
Low: 310.00
Prev. Close: 315.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: Record down as managed assets decline

Fri, 20th Oct 2023 10:02

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday.

----------

SMALL-CAP - WINNERS

----------

Regional REIT Ltd, up 4.4% at 27.52 pence, 12-month range 25.57p-69.60p. This is after the London-based real estate investment trust's share price falls 2.0% in the last five days and 49% in the last six months. Last month, it reported a first half pretax loss of GBP12.1 million from a profit of GBP28.3 million a year earlier.

----------

Oxford BioMedica PLC, up 3.7% at 260.26p, 12-month range 236.50p-575.00p. This is after the Oxfordshire, England-based gene and cell therapy group's share price falls 7.8% in the last five days and 39% in the last six months. Last month, it reported that its first half pretax loss widened to GBP52.3 million from GBP27.4 million, although shares rose on noting it was in exclusive talks to buy ABL Europe from Institut Merieux SA for EUR15 million.

----------

SMALL-CAP - LOSERS

----------

Record PLC, down 4.9% at 69.4p, 12-month range 68.12p-102.00p. The currency and derivatives manager said that plans for diversification are progressing well, despite seeing assets under management decline in the second quarter. For the three months ended September 30, it says assets under management equivalents fell to USD84.5 million, from USD86.4 million at the end of June. Dynamic hedging assets under management fall 5.2% to USD14.5 billion from USD15.3 billion in the first quarter, while passive hedging assets fall 1.8% to USD60.5 billion from USD61.6 billion. "Our plans for diversification through our asset management and digital asset businesses continue to progress well, albeit in places more gradually than initially envisaged, and I look forward to giving more detail on our strategic progress at our forthcoming half-year results in November," says Chief Executive Leslie Hill.

----------

Sabre Insurance Group PLC, down 4.3% at 145.5p, 12-month range 81.90p-168.00p. Barclays raises its price target for the Dorking, England-based motor insurance underwriter to 171p from 157p, rating the stock at 'overweight'. Sabre Insurance shares were up 3.3% at 155.00p in London on Thursday around noon, after celebrating a sharp increase in gross written premiums in the last nine months, despite Motorcycle premiums plummeting. It also raised its full-year guidance. Gross written premiums increased 20% in the nine months ended September 30, to GBP162.2 million from GBP135.7 million. In 2022, they totalled GBP171.3 million.

----------

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
10 Sep 2020 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
9 Sep 2020 08:31

Oxford Biomedica slumps as AstraZeneca vaccine trial halted

(Sharecast News) - Oxford Biomedica shares slid on Wednesday on news that AstraZeneca and Oxford University's Covid-19 vaccine trial has been put on hold, as investors fretted over how this might affect the gene and cell therapy company's supply deal with the UK pharmaceuticals giant.

Read more
1 Sep 2020 10:27

UPDATE 2-AstraZeneca bolsters COVID-19 vaccine supply with new deal

* AZ reserves production capacity at Oxford Biomedica plant* Deal could be expanded beyond new term of 18 months* AZ's drug, Imfinzi, also wins EU okay for aggressive lung cancer* AZ shares rise 1.5%, Oxford Biomedica up 2% (Adds comment on agreeme...

Read more
1 Sep 2020 10:27

CORRECTED-UPDATE 2-AstraZeneca bolsters COVID-19 vaccine supply with new deal

(Corrects para 3 to say EU (not U.S.) approval for Imfinzi)* AZ reserves production capacity at Oxford Biomedica plant* Deal could be expanded beyond new term of 18 months* AZ's drug, Imfinzi, also wins EU okay for aggressive lung cancer* AZ shares ...

Read more
1 Sep 2020 10:00

UPDATE 2-FTSE 100 falls to 15-week low after best August since 2014

(For a live blog on European stocks, type LIVE/ in an Eikon news window.)* FTSE 100 hit by strong pound, marks worst day since late July* Oxford Biomedica rises as AstraZeneca expands supply tie-up* British factory activity improves in August* Hom...

Read more
1 Sep 2020 08:29

UPDATE: Astra, Oxford Biomedica Expand Covid-19 Vaccine Supply Deal

UPDATE: Astra, Oxford Biomedica Expand Covid-19 Vaccine Supply Deal

Read more
1 Sep 2020 07:54

LONDON BRIEFING: Oxford Biomedica And Astra Expand Vaccine Supply Pact

LONDON BRIEFING: Oxford Biomedica And Astra Expand Vaccine Supply Pact

Read more
1 Sep 2020 07:54

CORRECTED-UPDATE 1-AstraZeneca, Oxford Biomedica expand COVID-19 vaccine supply tie-up

(Corrects currency in second paragraph to pounds from dollars)Sept 1 (Reuters) - AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker's COVID-19 vaccine candidate, as it looks to scale-up supp...

Read more
1 Sep 2020 07:54

UPDATE 1-AstraZeneca, Oxford Biomedica expand COVID-19 vaccine supply tie-up

(Adds details on supply agreement, background)Sept 1 (Reuters) - AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker's COVID-19 vaccine candidate, as it looks to scale-up supply ahead of a po...

Read more
1 Sep 2020 07:42

LONDON MARKET PRE-OPEN: Dunelm Sees Rise In Sales From Pent Up Demand

LONDON MARKET PRE-OPEN: Dunelm Sees Rise In Sales From Pent Up Demand

Read more
1 Sep 2020 07:35

CORRECTED-AstraZeneca expands COVID-19 vaccine supply tie-up with Oxford Biomedica

(Corrects currency in first paragraph to pounds from dollars)Sept 1 (Reuters) - AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell t...

Read more
1 Sep 2020 07:35

AstraZeneca expands COVID-19 vaccine supply tie-up with Oxford Biomedica

Sept 1 (Reuters) - AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell therapy firm $15 million upfront and an additional $35 millio...

Read more
3 Aug 2020 08:05

Oxford Biomedica signs deal with Beam Therapeutics

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics, it announced on Monday, which it described as a Massachusetts-based biotechnology company developing precision genetic medicines through the use of base editing.

Read more
31 Jul 2020 11:06

IN BRIEF: Oxford Biomedica And Axovant Sign Clinical Supply Deal

IN BRIEF: Oxford Biomedica And Axovant Sign Clinical Supply Deal

Read more
31 Jul 2020 08:34

Oxford Biomedica signs supply deal with Axovant Gene Therapies

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a three-year clinical supply agreement with a wholly-owned subsidiary of Axovant Gene Therapies, it announced on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.